Jinghua Aims To Transform Through Kadmon Biologics Alliance
This article was originally published in PharmAsia News
China-listed Jinghua Pharmaceutical has tapped into developing biologic drug through investment and licensing agreement with US-based Kadmon, shifting from a traditional Chinese medicine maker to mAbs developer. The company has seen increasing competition and revenue drops in Chinese traditional medicine industry.
Register for our free email digests: